WO2005016326A3 - Analogues de la thalidomide utilises comme inhibiteurs potentiels de l'angiogenese - Google Patents

Analogues de la thalidomide utilises comme inhibiteurs potentiels de l'angiogenese Download PDF

Info

Publication number
WO2005016326A3
WO2005016326A3 PCT/US2004/022242 US2004022242W WO2005016326A3 WO 2005016326 A3 WO2005016326 A3 WO 2005016326A3 US 2004022242 W US2004022242 W US 2004022242W WO 2005016326 A3 WO2005016326 A3 WO 2005016326A3
Authority
WO
WIPO (PCT)
Prior art keywords
thalidomide
analogs
angiogenesis inhibitors
potential angiogenesis
subject
Prior art date
Application number
PCT/US2004/022242
Other languages
English (en)
Other versions
WO2005016326A2 (fr
Inventor
William D Figg
Frederick Luzzio
Kurt Eger
Michael Weiss
Sunna Hauschildt
Thomas Hecker
Erin R Lepper
Original Assignee
Us Gov Health & Human Serv
William D Figg
Frederick Luzzio
Kurt Eger
Michael Weiss
Sunna Hauschildt
Thomas Hecker
Erin R Lepper
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Gov Health & Human Serv, William D Figg, Frederick Luzzio, Kurt Eger, Michael Weiss, Sunna Hauschildt, Thomas Hecker, Erin R Lepper filed Critical Us Gov Health & Human Serv
Publication of WO2005016326A2 publication Critical patent/WO2005016326A2/fr
Publication of WO2005016326A3 publication Critical patent/WO2005016326A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/65—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to carbon atoms of unsubstituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/20—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals substituted additionally by nitrogen atoms, e.g. tryptophane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/86—Oxygen atoms
    • C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention porte sur des procédés d'inhibition de l'angiogenèse qui consistent à administrer à un sujet une quantité efficace d'un point de vue thérapeutique d'au moins un analogue de la thalidomide ou de ses sels acceptables d'un point de vue pharmaceutique. Selon une autre variante, les composés sélectionnés peuvent être administrés pour traiter une tumeur chez un sujet.
PCT/US2004/022242 2003-07-11 2004-07-09 Analogues de la thalidomide utilises comme inhibiteurs potentiels de l'angiogenese WO2005016326A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48651503P 2003-07-11 2003-07-11
US60/486,515 2003-07-11

Publications (2)

Publication Number Publication Date
WO2005016326A2 WO2005016326A2 (fr) 2005-02-24
WO2005016326A3 true WO2005016326A3 (fr) 2005-06-16

Family

ID=34193060

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/022242 WO2005016326A2 (fr) 2003-07-11 2004-07-09 Analogues de la thalidomide utilises comme inhibiteurs potentiels de l'angiogenese

Country Status (1)

Country Link
WO (1) WO2005016326A2 (fr)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7320991B2 (en) 2001-02-27 2008-01-22 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, National Institutes Of Health Analogs of thalidomide as potential angiogenesis inhibitors
US8952895B2 (en) 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
CA2808646C (fr) 2003-09-17 2016-08-23 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Analogues de la thalidomide comme modulateurs tnf-alpha
CA2648216C (fr) 2006-04-13 2016-06-07 Michael Gutschow Composes tetrahalogenes utilises comme inhibiteurs d'angiogenese
WO2008007979A1 (fr) * 2006-07-12 2008-01-17 Auckland Uniservices Limited Dérivés de l'acide benzoïque ayant des propriétés immunomodulatrices et anticancéreuses
WO2012031603A2 (fr) 2010-09-09 2012-03-15 Danish Medical Consults Aps Administration d'inhibiteurs d'angiogenèse par les voies aériennes
ES2617446T3 (es) 2010-09-27 2017-06-19 Morphosys Ag Anticuerpo anti-cd38 y lenalidomida o bortezomib para el tratamiento del mieloma múltiple y nhl
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds
ES2644022T3 (es) 2013-03-14 2017-11-27 Bristol-Myers Squibb Company Combinación de un agonista de DR5 y un antagonista de anti-PD-1 y métodos de uso
US9694084B2 (en) 2014-12-23 2017-07-04 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
CN107257800B (zh) 2014-12-23 2020-06-30 达纳-法伯癌症研究所股份有限公司 通过双功能分子诱导靶蛋白降解的方法
ES2832475T3 (es) * 2016-01-08 2021-06-10 Celgene Corp Compuestos antiproliferativos y sus composiciones farmacéuticas y usos
MX2018011216A (es) 2016-03-16 2019-08-29 H Lee Moffitt Cancer Ct & Res Moléculas pequeñas contra cereblon para mejorar la función efectora de los linfocitos t.
SI3465214T1 (sl) 2016-05-30 2021-12-31 Morphosys Ag Postopki za napovedovanje terapevtske koristi terapije proti CD19 pri pacientih
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
CN106806366B (zh) * 2016-12-29 2020-02-11 兰州大学 一种异吲哚-1，3-二酮类化合物的新用途
US20200199097A1 (en) * 2017-08-21 2020-06-25 Nanjing Noratech Pharmaceuticals Co., Ltd Pomalidomide derivative and preparation method therefor
US10513515B2 (en) 2017-08-25 2019-12-24 Biotheryx, Inc. Ether compounds and uses thereof
CN107698648B (zh) * 2017-08-30 2020-08-14 大连理工大学 含胆甾醇的萘酰亚胺类衍生物及其合成和应用
KR20210032430A (ko) 2018-07-11 2021-03-24 에이치 리 모피트 캔서 센터 앤드 리서어치 인스티튜트 아이엔씨 세레블론-기반 메커니즘에 대한 이량체 면역-조절 화합물
US11236103B2 (en) 2018-07-27 2022-02-01 Biotheryx, Inc. Bifunctional compounds
WO2020041331A1 (fr) 2018-08-20 2020-02-27 Arvinas Operations, Inc. Composé chimère ciblant la protéolyse (protac) ayant une activité de liaison à l'ubiquitine ligase e3 et ciblant une protéine alpha-synucléine pour le traitement de maladies neurodégénératives
CN111499610A (zh) * 2019-01-31 2020-08-07 南京诺瑞特医药科技有限公司 泊马度胺前体药物盐的多晶型物
SG11202111343TA (en) 2019-05-03 2021-11-29 Morphosys Ag Anti-cd19 therapy in patients having a limited number of nk cells
EP3999182A1 (fr) 2019-07-17 2022-05-25 Arvinas Operations, Inc. Composés ciblant la protéine tau et procédés d'utilisation associés
KR20220103969A (ko) 2019-10-31 2022-07-25 모르포시스 아게 백혈병 또는 림프종의 치료를 위해 레날리도마이드와 조합된 항-cd19 요법
CN114786723A (zh) 2019-10-31 2022-07-22 莫佛塞斯公司 序贯抗cd19疗法
WO2021222150A2 (fr) 2020-04-28 2021-11-04 Anwita Biosciences, Inc. Polypeptides d'interleukine-2 et protéines de fusion de ceux-ci, ainsi que leurs compositions pharmaceutiques et leurs applications thérapeutiques
EP3915556A1 (fr) 2020-05-27 2021-12-01 Franz Josef Vonnahme Application rectale de thalidomide chez des patients atteints de rectite radique chronique hémorragique
CN117327059A (zh) * 2020-07-08 2024-01-02 北京泰德制药股份有限公司 抑制并诱导蛋白降解的化合物
CN118388454A (zh) 2021-04-16 2024-07-26 阿尔维纳斯运营股份有限公司 Bcl6蛋白水解的调节剂和其相关使用方法
WO2024054591A1 (fr) 2022-09-07 2024-03-14 Arvinas Operations, Inc. Composés de dégradation de fibrosarcome rapidement accéléré (raf) et procédés d'utilisation associés

Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB962857A (en) * 1961-12-04 1964-07-08 Distillers Co Yeast Ltd Process for the production of imides
US3314953A (en) * 1964-03-16 1967-04-18 Richardson Merrell Inc 1-substituted-3-phthalimido-2, 5-dioxopyrrolidines
GB1075420A (en) * 1965-05-08 1967-07-12 Gruenenthal Chemie Cyclic imide compounds and a process for their production
US3560495A (en) * 1965-05-08 1971-02-02 Ernst Frankus 1-heterocyclic amino methyl or 1-heterocyclic hydrazino methyl-3-phthalimido or (3',6'-dithia-3',4',5',6'-tetrahydrophthalimido)-pyrrolidinediones-2,5 or piperidinediones-2,6
US4092147A (en) * 1975-11-12 1978-05-30 American Cyanamid Company Method for controlling the relative stem growth of plants
US4291048A (en) * 1978-07-06 1981-09-22 Joseph Gold Method of treating tumors and cancerous cachexia with L-tryptophan
DE3332633A1 (de) * 1983-09-09 1985-04-04 Luitpold-Werk Chemisch-pharmazeutische Fabrik GmbH & Co, 8000 München Substituierte carbonsaeurederivate, verfahren zu ihrer herstellung, und arzneimittel
WO1994020085A1 (fr) * 1993-03-01 1994-09-15 The Children's Medical Center Corporation Procedes et compositions pour inhiber l'angiogenese
WO1997012625A1 (fr) * 1995-10-03 1997-04-10 Cytran, Ltd. Compositions pharmaceutiques a base de dipeptide angiostatique et leur procede d'utilisation
WO1997037988A1 (fr) * 1996-04-09 1997-10-16 Grünenthal GmbH Promedicaments acyles de la n-hydroxymethylthalidomide a effet immunomodulateur
WO1998025895A1 (fr) * 1996-12-13 1998-06-18 Eli Lilly And Company Inhibiteurs de l'activite enzymatique de l'antigene psa
US5783605A (en) * 1995-02-27 1998-07-21 Kuo; Sheng-Chu Helper inducers for differentiation therapy and chemoprevention of cancer
US5789434A (en) * 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
WO1999013873A1 (fr) * 1997-09-15 1999-03-25 Klavdia Stepanovna Evlanenkova Agent permettant de traiter des malades souffrant de tumeurs
WO2002064083A2 (fr) * 2000-11-30 2002-08-22 The Children's Medical Center Corporation Synthese de 3-amino-thalidomide et de ses enantiomeres
WO2003014315A2 (fr) * 2001-08-06 2003-02-20 The Children's Medical Center Corporation Synthese et activite antitumorale d'analogues de thalidomide substitues par azote
WO2003097052A2 (fr) * 2002-05-17 2003-11-27 Celgene Corporation Methodes et compositions faisant appel a des composes immunomodulateurs pour le traitement et la prise en charge des cancers et d'autres maladies
WO2004085422A1 (fr) * 2003-03-27 2004-10-07 Tian Jin Hemay Bio-Tech Co., Ltd. Derives de thalidomide hydrosoluble

Patent Citations (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB962857A (en) * 1961-12-04 1964-07-08 Distillers Co Yeast Ltd Process for the production of imides
US3314953A (en) * 1964-03-16 1967-04-18 Richardson Merrell Inc 1-substituted-3-phthalimido-2, 5-dioxopyrrolidines
GB1075420A (en) * 1965-05-08 1967-07-12 Gruenenthal Chemie Cyclic imide compounds and a process for their production
US3560495A (en) * 1965-05-08 1971-02-02 Ernst Frankus 1-heterocyclic amino methyl or 1-heterocyclic hydrazino methyl-3-phthalimido or (3',6'-dithia-3',4',5',6'-tetrahydrophthalimido)-pyrrolidinediones-2,5 or piperidinediones-2,6
US4092147A (en) * 1975-11-12 1978-05-30 American Cyanamid Company Method for controlling the relative stem growth of plants
US4291048A (en) * 1978-07-06 1981-09-22 Joseph Gold Method of treating tumors and cancerous cachexia with L-tryptophan
DE3332633A1 (de) * 1983-09-09 1985-04-04 Luitpold-Werk Chemisch-pharmazeutische Fabrik GmbH & Co, 8000 München Substituierte carbonsaeurederivate, verfahren zu ihrer herstellung, und arzneimittel
WO1994020085A1 (fr) * 1993-03-01 1994-09-15 The Children's Medical Center Corporation Procedes et compositions pour inhiber l'angiogenese
US5789434A (en) * 1994-11-15 1998-08-04 Bayer Corporation Derivatives of substituted 4-biarylbutyric acid as matrix metalloprotease inhibitors
US5783605A (en) * 1995-02-27 1998-07-21 Kuo; Sheng-Chu Helper inducers for differentiation therapy and chemoprevention of cancer
WO1997012625A1 (fr) * 1995-10-03 1997-04-10 Cytran, Ltd. Compositions pharmaceutiques a base de dipeptide angiostatique et leur procede d'utilisation
WO1997037988A1 (fr) * 1996-04-09 1997-10-16 Grünenthal GmbH Promedicaments acyles de la n-hydroxymethylthalidomide a effet immunomodulateur
WO1998025895A1 (fr) * 1996-12-13 1998-06-18 Eli Lilly And Company Inhibiteurs de l'activite enzymatique de l'antigene psa
WO1999013873A1 (fr) * 1997-09-15 1999-03-25 Klavdia Stepanovna Evlanenkova Agent permettant de traiter des malades souffrant de tumeurs
WO2002064083A2 (fr) * 2000-11-30 2002-08-22 The Children's Medical Center Corporation Synthese de 3-amino-thalidomide et de ses enantiomeres
WO2003014315A2 (fr) * 2001-08-06 2003-02-20 The Children's Medical Center Corporation Synthese et activite antitumorale d'analogues de thalidomide substitues par azote
WO2003097052A2 (fr) * 2002-05-17 2003-11-27 Celgene Corporation Methodes et compositions faisant appel a des composes immunomodulateurs pour le traitement et la prise en charge des cancers et d'autres maladies
WO2004085422A1 (fr) * 2003-03-27 2004-10-07 Tian Jin Hemay Bio-Tech Co., Ltd. Derives de thalidomide hydrosoluble

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
"THE MERCK INDEX", 2001, MERCK & CO., XP002322662 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 7 October 2004 (2004-10-07), ZHANG, HESHENG: "Preparation of water-soluble thalidomide derivatives", XP002308491, retrieved from STN Database accession no. 2004:817880 *
DATABASE WPI Section Ch Week 199919, Derwent World Patents Index; Class B02, AN 1998-592576 *
DATABASE WPI Section Ch Week 200470, Derwent World Patents Index; Class B02, AN 2004-719020 *
DE A U ET AL: "POSSIBLE ANTINEOPLASTIC AGENTS: III SYNTHESIS OF 6-ALKYL-2- U4'METHOXYPHTHALIMIDO AND 6-ALKYL-3-U3'-4'-DIMETHOXYPHENYL GLUTARIMIDES", JOURNAL OF THE INDIAN CHEMICAL SOCIETY, THE INDIAN CHEMICAL SOCIETY, CALCUTTA, IN, vol. 53, no. 11, 1 November 1976 (1976-11-01), pages 1122 - 1125, XP000675187, ISSN: 0019-4522 *
DE A U ET AL: "POSSIBLE ANTINEOPLASTIC AGENTS: PART IV - SYNTHESIS & ANTINEOPLASTIC POTENCY OF N-SUBSTITUTED ALPHA-(4,5-DIMETHOXYPHTHALIMIDO)GLUTARIMIDES & N-SUBSTITUTED BETA-(4-BROMOPHENYL)GLUTARIMIDES", INDIAN JOURNAL OF CHEMISTRY, SECTION B: ORGANIC, INCL. MEDICINAL, PUBLICATIONS & INFORMATIONS DIRECTORATE, NEW DELHI, IN, vol. 16B, no. 6, 1 June 1978 (1978-06-01), pages 510 - 512, XP000675183, ISSN: 0019-5103 *
FOLKES L K ET AL: "Oxidative activation of indole-3-acetic acids to cytotoxic species- a potential new role for plant auxins in cancer therapy.", BIOCHEMICAL PHARMACOLOGY. 15 JAN 2001, vol. 61, no. 2, 15 January 2001 (2001-01-15), pages 129 - 136, XP008044869, ISSN: 0006-2952 *
HESS, S. ET AL: "Synthesis and immunological activity of water-soluble thalidomide prodrugs", BIOORGANIC & MEDICINAL CHEMISTRY , 9(5), 1279-1291 CODEN: BMECEP; ISSN: 0968-0896, 2001, XP001202654 *
KARBOWNIK M ET AL: "Indole-3-propionic acid, a melatonin-related molecule, protects hepatic microsomal membranes from iron-induced oxidative damage: relevance to cancer reduction.", JOURNAL OF CELLULAR BIOCHEMISTRY. 2001, vol. 81, no. 3, 2001, pages 507 - 513, XP008044870, ISSN: 0730-2312 *
LENTZSCH S ET AL: "S-3-amino-phthalimido-glutarimide inhibits angiogenesis and growth of B-cell neoplasias in mice", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, BALTIMORE, MD, US, vol. 62, 15 April 2002 (2002-04-15), pages 2300 - 2305, XP002959459, ISSN: 0008-5472 *
LEPPER, ERIN R. ET AL: "Comparative Molecular Field Analysis and Comparative Molecular Similarity Indices Analysis of Thalidomide Analogues as Angiogenesis Inhibitors", JOURNAL OF MEDICINAL CHEMISTRY , 47(9), 2219-2227 CODEN: JMCMAR; ISSN: 0022-2623, 2004, XP001202667 *
NG, SYLVIA S. W. ET AL: "Antiangiogenic Activity of N-substituted and Tetrafluorinated Thalidomide Analogues", CANCER RESEARCH , 63(12), 3189-3194 CODEN: CNREA8; ISSN: 0008-5472, 15 June 2003 (2003-06-15), XP001202664 *
SEDLAK M ET AL: "Preparation, 1H and 13C NMR spectra of substituted 2-benzoylaminocarboxamides", COLLECTION OF CZECHOSLOVAK CHEMICAL COMMUNICATIONS, ACADEMIC PRESS, LONDON, GB, vol. 60, 1995, pages 150 - 160, XP002136842, ISSN: 0010-0765 *
SUZUKI, MAMORU ET AL: "Use of a new protecting group in an attempted synthesis of cyclopropyldihydroxyphenylalanine", JOURNAL OF ORGANIC CHEMISTRY , 48(24), 4769-71 CODEN: JOCEAH; ISSN: 0022-3263, 1983, XP008044808 *

Also Published As

Publication number Publication date
WO2005016326A2 (fr) 2005-02-24

Similar Documents

Publication Publication Date Title
WO2005016326A3 (fr) Analogues de la thalidomide utilises comme inhibiteurs potentiels de l'angiogenese
WO2008022256A3 (fr) Procédés et compositions de prévention ou de traitement de maladies liées au vieillissement
ATE440603T1 (de) 8-hydroxychinolinderivate
WO2005097125A3 (fr) Methodes et compositions pour le traitement, la prevention ou la gestion des troubles du sommeil et des troubles du sommeil associes a une maladie
GEP20084439B (en) Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof
HK1120441A1 (en) Drugs for treatment of ovarian cancer
WO2008064107A3 (fr) 7,8-dihydro-1,6-naphthyridin-5(6h)-ones et composés bicycliques apparentés comme inhibiteurs de la dipeptidyl peptidase iv et procédés
MX346186B (es) Inhibidores de proteina cinasas.
DOP2005000039A (es) Hidrocloruro de [4-(5-aminometil-2-fluoro-fenil)- piperidin-1-il]-(4-bomo-3-metil-5-propoxi-tiofen-2-il)-metanona como un inhibidor de la triptasa de mastocitos
WO2005002582A3 (fr) Composes actifs de trp-p8 et methodes de traitement therapeutique
WO2007062093A3 (fr) Polytherapie pour le traitement du cancer
WO2008151288A3 (fr) Composés aromatiques et hétéroaromatiques utiles dans le traitement de troubles du métabolisme du fer
WO2005004808A3 (fr) Composes tetracycliques utilises comme inhibiteurs de c-met
WO2013085849A3 (fr) Esters de sulfate de noribogaïne
WO2006068796A3 (fr) Inhibiteurs de l'activite de akt
MX2021002878A (es) Inhibidores de cd73 y usos farmaceuticos de los mismos.
JOP20220075A1 (ar) مثبطات عامل d المكمل عن طريق الفم
WO2006079077A3 (fr) Composes en tant que modulateurs de recepteur de ghreline et leurs utilisations
CR20220196A (es) Inhibidores del factor d del complemento para administración oral
MX2023012120A (es) Inhibidores heteroaromaticos biciclicos de la klk5.
WO2006031719A3 (fr) Composes de 1,4-bis-n-oxyde-5,8-dihydroxyanthracenedione et leur utilisation
WO2003051290A3 (fr) Traitement de maladies mediees par les lymphocytes b par modulation de l'activite du dr6
WO2005113011A3 (fr) Promedicaments de composes modulant les canaux ioniques et leurs utilisations
WO2007092436A3 (fr) Composes pour le traitement de troubles inflammatoires, de troubles de demyelinisation et de cancers
WO2004043360A3 (fr) Procedes d'utilisation de composes de vitamine d pour traiter des syndromes myelodysplasiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase